Somatostatin Receptor Imaging in Nasopharyngeal Cancer, Epstein-Barr Virus (EBV) Related Cancers and Other Rare Tumors
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Amount of tracer uptake in the tumour lesions of NPC patients
研究概览
简要总结
The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations
- •Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging
- •Histologically confirmed NPC
- •Above 21 years of age
排除标准
- •Patients below 21 years of age
- •Pregnant and breast feeding ladies
结局指标
主要结局
Amount of tracer uptake in the tumour lesions of NPC patients
时间窗: From time of tracer injection to time the scan is performed
The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.
次要结局
- Number of somatostatin receptors in patient biopsy samples(Upon signing the informed consent form)
- Amount of tracer uptake in the tumour lesions of patients with EBV related cancers(From time of tracer injection to time the scan is performed)
- Amount of somatostatin circulating tumour cells in patient blood samples(At the time of scan)